{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:33:44Z","timestamp":1785800024803,"version":"3.56.0"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41585-025-01098-4","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:42:16Z","timestamp":1761835336000},"page":"266-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing local control in the surgical management of bladder cancer"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-1143","authenticated-orcid":false,"given":"Martin","family":"Egger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent D.","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8640-1636","authenticated-orcid":false,"given":"Clara","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnamdi O.","family":"Onochie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7343","authenticated-orcid":false,"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mossanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"1098_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1098_CR2","unstructured":"Survival Rates for Bladder Cancer. American Cancer Society https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/detection-diagnosis-staging\/survival-rates.html (2025)."},{"key":"1098_CR3","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.21037\/tau.2020.03.23","volume":"9","author":"K Aminoltejari","year":"2020","unstructured":"Aminoltejari, K. & Black, P. C. Radical cystectomy: a review of techniques, developments and controversies. Transl. Androl. Urol. 9, 3073\u20133081 (2020).","journal-title":"Transl. Androl. Urol."},{"key":"1098_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/1097-0142(194905)2:3<424::AID-CNCR2820020306>3.0.CO;2-Y","volume":"2","author":"VJ Marshall","year":"1949","unstructured":"Marshall, V. J. & Whitemore, W. F. A technique for the extension of radical surgery in the treatment of vesical cancer. Cancer 2, 424\u2013428 (1949).","journal-title":"Cancer"},{"key":"1098_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1464-410X.1989.tb05122.x","volume":"63","author":"UE Studer","year":"1989","unstructured":"Studer, U. E., Ackermann, D., Casanova, G. A. & Zingg, E. J. Three years\u2019 experience with an ileal low pressure bladder substitute. Br. J. Urol. 63, 43\u201352 (1989).","journal-title":"Br. J. Urol."},{"key":"1098_CR6","doi-asserted-by":"publisher","first-page":"6845","DOI":"10.3390\/jcm12216845","volume":"12","author":"VD D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea, V. D. et al. Evidence-based analysis of the critical steps of radical cystectomy for bladder cancer. J. Clin. Med. 12, 6845 (2023).","journal-title":"J. Clin. Med."},{"key":"1098_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"JWF Catto","year":"2021","unstructured":"Catto, J. W. F. et al. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur. Urol. 79, 621\u2013632 (2021).","journal-title":"Eur. Urol."},{"key":"1098_CR8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/03007995.2020.1758927","volume":"36","author":"E Malangone-Monaco","year":"2020","unstructured":"Malangone-Monaco, E. et al. Cost of cystectomy-related complications in patients with bladder cancer in the United States. Curr. Med. Res. Opin. 36, 1177\u20131185 (2020).","journal-title":"Curr. Med. Res. Opin."},{"key":"1098_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bju.15132","volume":"126","author":"E van der Vlies","year":"2020","unstructured":"van der Vlies, E. et al. Preoperative frailty and outcome in patients undergoing radical cystectomy. BJU Int. 126, 388\u2013395 (2020).","journal-title":"BJU Int."},{"key":"1098_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111281","volume":"9","author":"LT Lavall\u00e9e","year":"2014","unstructured":"Lavall\u00e9e, L. T. et al. Peri-operative morbidity associated with radical cystectomy in a multicenter database of community and academic hospitals. PLoS ONE 9, e111281 (2014).","journal-title":"PLoS ONE"},{"key":"1098_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","volume":"55","author":"A Shabsigh","year":"2009","unstructured":"Shabsigh, A. et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur. Urol. 55, 164\u2013174 (2009).","journal-title":"Eur. Urol."},{"key":"1098_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/cncr.31799","volume":"125","author":"SL Woldu","year":"2019","unstructured":"Woldu, S. L., Sanli, O., Clinton, T. N. & Lotan, Y. Validating the predictors of outcomes after radical cystectomy for bladder cancer. Cancer 125, 223\u2013231 (2019).","journal-title":"Cancer"},{"key":"1098_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/bja\/78.5.606","volume":"78","author":"H Kehlet","year":"1997","unstructured":"Kehlet, H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br. J. Anaesth. 78, 606\u2013617 (1997).","journal-title":"Br. J. Anaesth."},{"key":"1098_CR14","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.clnu.2013.09.014","volume":"32","author":"Y Cerantola","year":"2013","unstructured":"Cerantola, Y. et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: enhanced recovery after surgery (ERAS\u00ae) society recommendations. Clin. Nutr. 32, 879\u2013887 (2013).","journal-title":"Clin. Nutr."},{"key":"1098_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2020.06.039","volume":"78","author":"SB Williams","year":"2020","unstructured":"Williams, S. B. et al. Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis. Eur. Urol. 78, 719\u2013730 (2020).","journal-title":"Eur. Urol."},{"key":"1098_CR16","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.juro.2015.05.083","volume":"194","author":"W Xu","year":"2015","unstructured":"Xu, W. et al. Postoperative pain management after radical cystectomy: comparing traditional versus enhanced recovery protocol pathway. J. Urol. 194, 1209\u20131213 (2015).","journal-title":"J. Urol."},{"key":"1098_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.euf.2018.08.025","volume":"6","author":"HA Chiang","year":"2020","unstructured":"Chiang, H. A. et al. Implementation of a perioperative venous thromboembolism prophylaxis program for patients undergoing radical cystectomy on an enhanced recovery after surgery protocol. Eur. Urol. Focus. 6, 74\u201380 (2020).","journal-title":"Eur. Urol. Focus."},{"key":"1098_CR18","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.ejso.2018.08.028","volume":"44","author":"ETD Souwer","year":"2018","unstructured":"Souwer, E. T. D. et al. Comprehensive multidisciplinary care program for elderly colorectal cancer patients: \u2018From prehabilitation to independence\u2019. Eur. J. Surg. Oncol. 44, 1894\u20131900 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"1098_CR19","doi-asserted-by":"publisher","first-page":"108.e19","DOI":"10.1016\/j.urolonc.2022.10.017","volume":"41","author":"WW Smelser","year":"2023","unstructured":"Smelser, W. W. et al. Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy. Urol. Oncol. 41, 108.e19\u2013108.e27 (2023).","journal-title":"Urol. Oncol."},{"key":"1098_CR20","first-page":"E8","volume":"17","author":"M Koelker","year":"2023","unstructured":"Koelker, M. et al. Impact of exercise on physical health status in bladder cancer patients. Can. Urol. Assoc. J. 17, E8\u2013E14 (2023).","journal-title":"Can. Urol. Assoc. J."},{"key":"1098_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071304","volume":"13","author":"E Akdemir","year":"2023","unstructured":"Akdemir, E. et al. EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial. BMJ Open. 13, e071304 (2023).","journal-title":"BMJ Open."},{"key":"1098_CR22","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05480735 (2022)."},{"key":"1098_CR23","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06040762 (2025)."},{"key":"1098_CR24","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05714826 (2025)."},{"key":"1098_CR25","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06002269 (2025)."},{"key":"1098_CR26","unstructured":"Mossanen, M. Patient-Centered Surgical Prehabilitation. US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05715684 (2023)."},{"key":"1098_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1046\/j.1464-410X.2003.04329.x","volume":"92","author":"M Menon","year":"2003","unstructured":"Menon, M. et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int. 92, 232\u2013236 (2003).","journal-title":"BJU Int."},{"key":"1098_CR28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1177\/000313481307900613","volume":"79","author":"M Salman","year":"2013","unstructured":"Salman, M. et al. Use, cost, complications, and mortality of robotic versus nonrobotic general surgery procedures based on a nationwide database. Am. Surg. 79, 553\u2013560 (2013).","journal-title":"Am. Surg."},{"key":"1098_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bju.12818","volume":"114","author":"JC Messer","year":"2014","unstructured":"Messer, J. C., Punnen, S., Fitzgerald, J., Svatek, R. & Parekh, D. J. Health-related quality of life from a prospective randomised clinical trial of robot-assisted laparoscopic vs open radical cystectomy. BJU Int. 114, 896\u2013902 (2014).","journal-title":"BJU Int."},{"key":"1098_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/JU.0000000000000565","volume":"203","author":"V Venkatramani","year":"2020","unstructured":"Venkatramani, V. et al. Predictors of recurrence, and progression-free and overall survival following open versus robotic radical cystectomy: analysis from the RAZOR Trial with a 3-year followup. J. Urol. 203, 522\u2013529 (2020).","journal-title":"J. Urol."},{"key":"1098_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2024.01.018","volume":"85","author":"R Mastroianni","year":"2024","unstructured":"Mastroianni, R. et al. Robot-assisted radical cystectomy with totally intracorporeal urinary diversion versus open radical cystectomy: 3-year outcomes from a randomised controlled trial. Eur. Urol. 85, 422\u2013430 (2024).","journal-title":"Eur. Urol."},{"key":"1098_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/BLC-220065","volume":"9","author":"NJ Sathianathen","year":"2023","unstructured":"Sathianathen, N. J. et al. Comparison of robotic vs open cystectomy: a systematic review. Bladder Cancer 9, 253\u2013269 (2023).","journal-title":"Bladder Cancer"},{"key":"1098_CR33","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/iju.14005","volume":"26","author":"S Kimura","year":"2019","unstructured":"Kimura, S. et al. Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: a systematic review and meta-analysis. Int. J. Urol. 26, 760\u2013774 (2019).","journal-title":"Int. J. Urol."},{"key":"1098_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.eururo.2009.10.024","volume":"57","author":"J Nix","year":"2010","unstructured":"Nix, J. et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur. Urol. 57, 196\u2013201 (2010).","journal-title":"Eur. Urol."},{"key":"1098_CR35","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.eururo.2014.11.043","volume":"67","author":"BH Bochner","year":"2015","unstructured":"Bochner, B. H. et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur. Urol. 67, 1042\u20131050 (2015).","journal-title":"Eur. Urol."},{"key":"1098_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.eururo.2018.04.030","volume":"74","author":"BH Bochner","year":"2018","unstructured":"Bochner, B. H. et al. Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes. Eur. Urol. 74, 465\u2013471 (2018).","journal-title":"Eur. Urol."},{"key":"1098_CR37","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","volume":"391","author":"DJ Parekh","year":"2018","unstructured":"Parekh, D. J. et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 391, 2525\u20132536 (2018).","journal-title":"Lancet"},{"key":"1098_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2015.07.038","volume":"69","author":"MS Khan","year":"2016","unstructured":"Khan, M. S. et al. A Single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur. Urol. 69, 613\u2013621 (2016).","journal-title":"Eur. Urol."},{"key":"1098_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eururo.2019.10.027","volume":"77","author":"MS Khan","year":"2020","unstructured":"Khan, M. S. et al. Long-term oncological outcomes from an early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur. Urol. 77, 110\u2013118 (2020).","journal-title":"Eur. Urol."},{"key":"1098_CR40","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/JU.0000000000002422","volume":"207","author":"R Mastroianni","year":"2022","unstructured":"Mastroianni, R. et al. Open radical cystectomy versus robot-assisted radical cystectomy with intracorporeal urinary diversion: early outcomes of a single-center randomized controlled trial. J. Urol. 207, 982\u2013992 (2022).","journal-title":"J. Urol."},{"key":"1098_CR41","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bju.15619","volume":"130","author":"SL Maibom","year":"2022","unstructured":"Maibom, S. L. et al. Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study. BJU Int. 130, 102\u2013113 (2022).","journal-title":"BJU Int."},{"key":"1098_CR42","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto, J. W. F. et al. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA 327, 2092\u20132103 (2022).","journal-title":"JAMA"},{"key":"1098_CR43","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1089\/end.2020.1227","volume":"35","author":"JT Gross","year":"2021","unstructured":"Gross, J. T. et al. Initial experience with single-port robot-assisted radical cystectomy: comparison of perioperative outcomes between single-port and conventional multiport approaches. J. Endourol. 35, 1177\u20131183 (2021).","journal-title":"J. Endourol."},{"key":"1098_CR44","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1089\/end.2023.0553","volume":"38","author":"AM Fang","year":"2024","unstructured":"Fang, A. M. et al. Postoperative outcomes and analgesic requirements of single-port vs multiport robotic-assisted radical cystectomy. J. Endourol. 38, 438\u2013443 (2024).","journal-title":"J. Endourol."},{"key":"1098_CR45","doi-asserted-by":"publisher","first-page":"7104","DOI":"10.3390\/s23167104","volume":"23","author":"A Brassetti","year":"2023","unstructured":"Brassetti, A. et al. Robotic surgery in urology: history from PROBOT\u00ae to HUGOTM. Sensors 23, 7104 (2023).","journal-title":"Sensors"},{"key":"1098_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.euros.2024.07.107","volume":"67","author":"Z Wu","year":"2024","unstructured":"Wu, Z. et al. Robot-assisted single-port radical prostatectomy with the SHURUI SP and da Vinci SP platforms: comparison of the technology, intraoperative performance, and outcomes. Eur. Urol. Open. Sci. 67, 26\u201337 (2024).","journal-title":"Eur. Urol. Open. Sci."},{"key":"1098_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.eururo.2023.04.004","volume":"84","author":"P Khetrapal","year":"2023","unstructured":"Khetrapal, P. et al. Robot-assisted radical cystectomy versus open radical cystectomy: a systematic review and meta-analysis of perioperative, oncological, and quality of life outcomes using randomized controlled trials. Eur. Urol. 84, 393\u2013405 (2023).","journal-title":"Eur. Urol."},{"key":"1098_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.euo.2019.11.005","volume":"3","author":"HM Bruins","year":"2020","unstructured":"Bruins, H. M. et al. The importance of hospital and surgeon volume as major determinants of morbidity and mortality after radical cystectomy for bladder cancer: a systematic review and recommendations by the European Association of Urology muscle-invasive and metastatic bladder cancer guideline panel. Eur. Urol. Oncol. 3, 131\u2013144 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1098_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00345-023-04742-z","volume":"42","author":"N Pyrgidis","year":"2024","unstructured":"Pyrgidis, N. et al. The effect of hospital caseload on perioperative mortality, morbidity and costs in bladder cancer patients undergoing radical cystectomy: results of the German nationwide inpatient data. World J. Urol. 42, 19 (2024).","journal-title":"World J. Urol."},{"key":"1098_CR50","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.eururo.2014.05.031","volume":"66","author":"HM Bruins","year":"2014","unstructured":"Bruins, H. M. et al. The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. Eur. Urol. 66, 1065\u20131077 (2014).","journal-title":"Eur. Urol."},{"key":"1098_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1442-2042.2011.02887.x","volume":"19","author":"JB Jensen","year":"2012","unstructured":"Jensen, J. B., Ulh\u00f8i, B. P. & Jensen, K. M.-E. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int. J. Urol. 19, 39\u201347 (2012).","journal-title":"Int. J. Urol."},{"key":"1098_CR52","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","volume":"75","author":"JE Gschwend","year":"2019","unstructured":"Gschwend, J. E. et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur. Urol. 75, 604\u2013611 (2019).","journal-title":"Eur. Urol."},{"key":"1098_CR53","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"391","author":"SP Lerner","year":"2024","unstructured":"Lerner, S. P. et al. Standard or extended lymphadenectomy for muscle-invasive bladder cancer. N. Engl. J. Med. 391, 1206\u20131216 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR54","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05899361 (2023)."},{"key":"1098_CR55","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov, A. et al. 3D Slicer as an image computing platform for the quantitative imaging network. Magn. Reson. Imaging 30, 1323\u20131341 (2012).","journal-title":"Magn. Reson. Imaging"},{"key":"1098_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05132283 (2023)."},{"key":"1098_CR57","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/RLU.0000000000004301","volume":"47","author":"DDD Rietbergen","year":"2022","unstructured":"Rietbergen, D. D. D. et al. Evaluation of the hybrid tracer indocyanine green- 99\u2009m tc-nanocolloid for sentinel node biopsy in bladder cancer-a prospective pilot study. Clin. Nucl. Med. 47, 774\u2013780 (2022).","journal-title":"Clin. Nucl. Med."},{"key":"1098_CR58","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/jso.27618","volume":"129","author":"L P\u00fcllen","year":"2024","unstructured":"P\u00fcllen, L. et al. Near-infrared fluorescence lymph node template region dissection plus backup lymphadenectomy in open radical cystectomy for bladder cancer using an innovative handheld device: a single center experience. J. Surg. Oncol. 129, 1325\u20131331 (2024).","journal-title":"J. Surg. Oncol."},{"key":"1098_CR59","doi-asserted-by":"publisher","first-page":"934.e11","DOI":"10.1016\/j.urolonc.2020.06.009","volume":"38","author":"C Palumbo","year":"2020","unstructured":"Palumbo, C. et al. Bladder cancer incidence rates and trends in young adults aged 20\u201339 years. Urol. Oncol. 38, 934.e11\u2013934.e19 (2020).","journal-title":"Urol. Oncol."},{"key":"1098_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes, J. A. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol. 79, 82\u2013104 (2021).","journal-title":"Eur. Urol."},{"key":"1098_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.urolonc.2024.01.008","volume":"42","author":"CP Dall","year":"2024","unstructured":"Dall, C. P. et al. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: a systematic review and meta-analysis. Urol. Oncol. 42, 121\u2013132 (2024).","journal-title":"Urol. Oncol."},{"key":"1098_CR62","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","volume":"81","author":"MB Clements","year":"2022","unstructured":"Clements, M. B. et al. Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort. Eur. Urol. 81, 294\u2013304 (2022).","journal-title":"Eur. Urol."},{"key":"1098_CR63","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0022-5347(17)43655-X","volume":"138","author":"PN Schlegel","year":"1987","unstructured":"Schlegel, P. N. & Walsh, P. C. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J. Urol. 138, 1402\u20131406 (1987).","journal-title":"J. Urol."},{"key":"1098_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000463924","volume":"18","author":"A Schilling","year":"1990","unstructured":"Schilling, A. & Friesen, A. Transprostatic selective cystectomy with an ileal bladder. Eur. Urol. 18, 253\u2013257 (1990).","journal-title":"Eur. Urol."},{"key":"1098_CR65","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0022-5347(05)68794-0","volume":"161","author":"A Spitz","year":"1999","unstructured":"Spitz, A., Stein, J. P., Lieskovsky, G. & Skinner, D. G. Orthotopic urinary diversion with preservation of erectile and ejaculatory function in men requiring radical cystectomy for nonurothelial malignancy: a new technique. J. Urol. 161, 1761\u20131764 (1999).","journal-title":"J. Urol."},{"key":"1098_CR66","doi-asserted-by":"publisher","first-page":"539.e17","DOI":"10.1016\/j.urolonc.2017.04.013","volume":"35","author":"V Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez, V. et al. Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: a systematic review. Urol. Oncol. 35, 539.e17\u2013539.e29 (2017).","journal-title":"Urol. Oncol."},{"key":"1098_CR67","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1464-410X.2010.09628.x","volume":"107","author":"RS Svatek","year":"2011","unstructured":"Svatek, R. S. et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 107, 898\u2013904 (2011).","journal-title":"BJU Int."},{"key":"1098_CR68","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000454736","volume":"98","author":"M Moschini","year":"2017","unstructured":"Moschini, M. et al. Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer. Urol. Int. 98, 290\u2013297 (2017).","journal-title":"Urol. Int."},{"key":"1098_CR69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ucl.2005.02.001","volume":"32","author":"RE Hautmann","year":"2005","unstructured":"Hautmann, R. E. & Stein, J. P. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol. Clin. North Am. 32, 177\u2013185 (2005).","journal-title":"Urol. Clin. North Am."},{"key":"1098_CR70","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.juro.2013.05.034","volume":"190","author":"HM Bruins","year":"2013","unstructured":"Bruins, H. M. et al. Incidental prostate cancer in patients with bladder urothelial carcinoma: comprehensive analysis of 1,476 radical cystoprostatectomy specimens. J. Urol. 190, 1704\u20131709 (2013).","journal-title":"J. Urol."},{"key":"1098_CR71","first-page":"678","volume":"9","author":"A Basiri","year":"2012","unstructured":"Basiri, A. et al. Overall survival and functional results of prostate-sparing cystectomy: a matched case-control study. Urol. J. 9, 678\u2013684 (2012).","journal-title":"Urol. J."},{"key":"1098_CR72","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/01.ju.0000138249.31644.ec","volume":"172","author":"TM Kessler","year":"2004","unstructured":"Kessler, T. M. et al. Attempted nerve sparing surgery and age have a significant effect on urinary continence and erectile function after radical cystoprostatectomy and ileal orthotopic bladder substitution. J. Urol. 172, 1323\u20131327 (2004).","journal-title":"J. Urol."},{"key":"1098_CR73","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.acuro.2013.02.012","volume":"37","author":"A Vilaseca","year":"2013","unstructured":"Vilaseca, A., Garc\u00eda-Cruz, E., Ribal, M. J., P\u00e9rez M\u00e1rquez, M. & Alcaraz, A. Erectile function after cystectomy with neurovascular preservation. Actas Urol. Esp. 37, 554\u2013559 (2013).","journal-title":"Actas Urol. Esp."},{"key":"1098_CR74","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/S0022-5347(05)01019-0","volume":"175","author":"MS el-Bahnasawy","year":"2006","unstructured":"el-Bahnasawy, M. S., Gomha, M. A. & Shaaban, A. A. Urethral pressure profile following orthotopic neobladder: differences between nerve sparing and standard radical cystectomy techniques. J. Urol. 175, 1759\u20131763 (2006). discussion 1763.","journal-title":"J. Urol."},{"key":"1098_CR75","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2008.06.072","volume":"55","author":"IA Hekal","year":"2009","unstructured":"Hekal, I. A., El-Bahnasawy, M. S., Mosbah, A., El-Assmy, A. & Shaaban, A. Recoverability of erectile function in post-radical cystectomy patients: subjective and objective evaluations. Eur. Urol. 55, 275\u2013283 (2009).","journal-title":"Eur. Urol."},{"key":"1098_CR76","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.eururo.2023.04.009","volume":"84","author":"A Martini","year":"2023","unstructured":"Martini, A. et al. Robot-assisted radical cystectomy with orthotopic neobladder reconstruction: techniques and functional outcomes in males. Eur. Urol. 84, 484\u2013490 (2023).","journal-title":"Eur. Urol."},{"key":"1098_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000499296","volume":"13","author":"AY Abdelaziz","year":"2019","unstructured":"Abdelaziz, A. Y. et al. Early oncological and functional outcomes of prostate capsule sparing cystectomy compared with standard radical cystectomy. Curr. Urol. 13, 37\u201345 (2019).","journal-title":"Curr. Urol."},{"key":"1098_CR78","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05067101 (2024)."},{"key":"1098_CR79","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bju.14850","volume":"125","author":"M Saad","year":"2020","unstructured":"Saad, M. et al. Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience. BJU Int. 125, 253\u2013259 (2020).","journal-title":"BJU Int."},{"key":"1098_CR80","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00345-015-1482-y","volume":"33","author":"R Colombo","year":"2015","unstructured":"Colombo, R. et al. Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients. World J. Urol. 33, 1389\u20131395 (2015).","journal-title":"World J. Urol."},{"key":"1098_CR81","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.juro.2014.07.090","volume":"193","author":"BL Jacobs","year":"2015","unstructured":"Jacobs, B. L. et al. Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial. J. Urol. 193, 64\u201370 (2015).","journal-title":"J. Urol."},{"key":"1098_CR82","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05792722 (2024)."},{"key":"1098_CR83","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bju.13819","volume":"120","author":"E Veskim\u00e4e","year":"2017","unstructured":"Veskim\u00e4e, E. et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int. 120, 12\u201324 (2017).","journal-title":"BJU Int."},{"key":"1098_CR84","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bju.16268","volume":"133","author":"N Lobo","year":"2024","unstructured":"Lobo, N. et al. Gynaecological organ involvement in females undergoing radical cystectomy: a multicentre study. BJU Int. 133, 474\u2013479 (2024).","journal-title":"BJU Int."},{"key":"1098_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ucl.2017.12.005","volume":"45","author":"S Avulova","year":"2018","unstructured":"Avulova, S. & Chang, S. S. Role and indications of organ-sparing \u2018radical\u2019 cystectomy: the importance of careful patient selection and counseling. Urol. Clin. North Am. 45, 199\u2013214 (2018).","journal-title":"Urol. Clin. North Am."},{"key":"1098_CR86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.urology.2021.06.002","volume":"156","author":"A Pacchetti","year":"2021","unstructured":"Pacchetti, A. et al. Sexual-sparing robot assisted radical cystectomy in female: a step-by-step guide. Urology 156, 322\u2013323 (2021).","journal-title":"Urology"},{"key":"1098_CR87","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.eururo.2007.02.048","volume":"52","author":"N Bhatta Dhar","year":"2007","unstructured":"Bhatta Dhar, N., Kessler, T. M., Mills, R. D., Burkhard, F. & Studer, U. E. Nerve-sparing radical cystectomy and orthotopic bladder replacement in female patients. Eur. Urol. 52, 1006\u20131014 (2007).","journal-title":"Eur. Urol."},{"key":"1098_CR88","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.juro.2012.08.024","volume":"188","author":"H Djaladat","year":"2012","unstructured":"Djaladat, H. et al. Reproductive organ involvement in female patients undergoing radical cystectomy for urothelial bladder cancer. J. Urol. 188, 2134\u20132138 (2012).","journal-title":"J. Urol."},{"key":"1098_CR89","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.4143\/crt.2018.515","volume":"51","author":"JS Shim","year":"2019","unstructured":"Shim, J. S. et al. Oncologic, perioperative outcomes of female radical cystectomy: results from a multicenter study in Korea. Cancer Res. Treat. 51, 1064\u20131072 (2019).","journal-title":"Cancer Res. Treat."},{"key":"1098_CR90","doi-asserted-by":"publisher","first-page":"E398","DOI":"10.5489\/cuaj.5086","volume":"12","author":"M Whittum","year":"2018","unstructured":"Whittum, M. et al. Gynecological organ involvement at robot-assisted radical cystectomy in females: is anterior exenteration necessary? Can. Urol. Assoc. J. 12, E398\u2013E402 (2018).","journal-title":"Can. Urol. Assoc. J."},{"key":"1098_CR91","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bju.14191","volume":"122","author":"T Gross","year":"2018","unstructured":"Gross, T. et al. Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome. BJU Int. 122, 227\u2013235 (2018).","journal-title":"BJU Int."},{"key":"1098_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-019-0951-z","volume":"20","author":"N Kalampokis","year":"2019","unstructured":"Kalampokis, N., Grivas, N., \u00d6lschl\u00e4ger, M., Hassan, F. N. & Gakis, G. Radical cystectomy in female patients \u2014 improving outcomes. Curr. Urol. Rep. 20, 83 (2019).","journal-title":"Curr. Urol. Rep."},{"key":"1098_CR93","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bju.16152","volume":"133","author":"E Laukhtina","year":"2024","unstructured":"Laukhtina, E. et al. Urinary function in female patients after traditional, organ-sparing and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analysis. BJU Int. 133, 246\u2013258 (2024).","journal-title":"BJU Int."},{"key":"1098_CR94","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2021.11.005","volume":"20","author":"SH Patel","year":"2022","unstructured":"Patel, S. H. et al. Safety and efficacy of reproductive organ-sparing radical cystectomy in women with variant histology and advanced stage. Clin. Genitourin. Cancer 20, 60\u201368 (2022).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1098_CR95","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/j.clgc.2023.01.010","volume":"21","author":"N Gupta","year":"2023","unstructured":"Gupta, N. et al. Practice patterns regarding female reproductive organ-sparing and nerve-sparing radical cystectomy among urologic oncologists in the United States. Clin. Genitourin. Cancer 21, e236\u2013e241 (2023).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1098_CR96","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.euros.2021.11.010","volume":"36","author":"E Lavall\u00e9e","year":"2022","unstructured":"Lavall\u00e9e, E. et al. Functional and oncological outcomes of female pelvic organ-preserving robot-assisted radical cystectomy. Eur. Urol. Open. Sci. 36, 34\u201340 (2022).","journal-title":"Eur. Urol. Open. Sci."},{"key":"1098_CR97","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.21037\/tau-22-463","volume":"11","author":"M von Deimling","year":"2022","unstructured":"von Deimling, M. et al. Radical cystectomy and urinary diversion in women: techniques, outcomes, and challenges-a narrative review. Transl. Androl. Urol. 11, 1598\u20131610 (2022).","journal-title":"Transl. Androl. Urol."},{"key":"1098_CR98","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06184516 (2025)."},{"key":"1098_CR99","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JU.0000000000003981","volume":"212","author":"J Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; Amended 2020, 2024). J. Urol. 212, 3\u201310 (2024).","journal-title":"J. Urol."},{"key":"1098_CR100","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"1098_CR101","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00345-015-1710-5","volume":"34","author":"E Suer","year":"2016","unstructured":"Suer, E. et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J. Urol. 34, 847\u2013851 (2016).","journal-title":"World J. Urol."},{"key":"1098_CR102","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477\u20131488 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.18.00537","volume":"37","author":"JJ Coen","year":"2019","unstructured":"Coen, J. J. et al. Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-A randomized phase II trial. J. Clin. Oncol. 37, 44\u201351 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR104","doi-asserted-by":"publisher","first-page":"1341655","DOI":"10.3389\/fonc.2024.1341655","volume":"14","author":"F Ghali","year":"2024","unstructured":"Ghali, F. et al. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Front. Oncol. 14, 1341655 (2024).","journal-title":"Front. Oncol."},{"key":"1098_CR105","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.clgc.2024.01.002","volume":"22","author":"C Lynch","year":"2024","unstructured":"Lynch, C. et al. Bladder-preserving trimodality therapy with capecitabine. Clin. Genitourin. Cancer 22, 476\u2013482.e1 (2024).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1098_CR106","doi-asserted-by":"publisher","first-page":"109584","DOI":"10.1016\/j.radonc.2023.109584","volume":"183","author":"A de Haar-Holleman","year":"2023","unstructured":"de Haar-Holleman, A. et al. Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study. Radiother. Oncol. 183, 109584 (2023).","journal-title":"Radiother. Oncol."},{"key":"1098_CR107","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","volume":"22","author":"A Choudhury","year":"2021","unstructured":"Choudhury, A. et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 22, 246\u2013255 (2021).","journal-title":"Lancet Oncol."},{"key":"1098_CR108","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","volume":"66","author":"G Ploussard","year":"2014","unstructured":"Ploussard, G. et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur. Urol. 66, 120\u2013137 (2014).","journal-title":"Eur. Urol."},{"key":"1098_CR109","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak, R. H. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J. Clin. Oncol. 32, 3801\u20133809 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR110","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","volume":"72","author":"RE Krasnow","year":"2017","unstructured":"Krasnow, R. E. et al. Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur. Urol. 72, 54\u201360 (2017).","journal-title":"Eur. Urol."},{"key":"1098_CR111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","volume":"42","author":"C Premo","year":"2015","unstructured":"Premo, C., Apolo, A. B., Agarwal, P. K. & Citrin, D. E. Trimodality therapy in bladder cancer: who, what, and when? Urol. Clin. North Am. 42, 169\u2013180 (2015). vii.","journal-title":"Urol. Clin. North Am."},{"key":"1098_CR112","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone, N. J. et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience. Eur. Urol. 71, 952\u2013960 (2017).","journal-title":"Eur. Urol."},{"key":"1098_CR113","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta, A. R. et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 24, 669\u2013681 (2023).","journal-title":"Lancet Oncol."},{"key":"1098_CR114","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","volume":"36","author":"O Fahmy","year":"2018","unstructured":"Fahmy, O. et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol. Oncol. 36, 43\u201353 (2018).","journal-title":"Urol. Oncol."},{"key":"1098_CR115","doi-asserted-by":"publisher","first-page":"7306198","DOI":"10.1155\/2022\/7306198","volume":"2022","author":"J Qiu","year":"2022","unstructured":"Qiu, J. et al. Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis. J. Oncol. 2022, 7306198 (2022).","journal-title":"J. Oncol."},{"key":"1098_CR116","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","volume":"187","author":"JR Eswara","year":"2012","unstructured":"Eswara, J. R. et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J. Urol. 187, 463\u2013468 (2012).","journal-title":"J. Urol."},{"key":"1098_CR117","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","volume":"199","author":"A Sanchez","year":"2018","unstructured":"Sanchez, A. et al. Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer. J. Urol. 199, 407\u2013415 (2018).","journal-title":"J. Urol."},{"key":"1098_CR118","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni, G. S. et al. Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J. Clin. Oncol. 35, 2299\u20132305 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR119","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.23.02510","volume":"42","author":"DM Dahl","year":"2024","unstructured":"Dahl, D. M. et al. Bladder-preserving trimodality treatment for high-grade t1 bladder cancer: results from phase II protocol NRG oncology\/RTOG 0926. J. Clin. Oncol. 42, 4095\u20134102 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.euo.2023.05.013","volume":"7","author":"DM Dahl","year":"2024","unstructured":"Dahl, D. M. et al. Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. final results of NRG oncology RTOG 0524-A Phase 1\/2 trial of paclitaxel\u2009+\u2009trastuzumab with daily radiation or paclitaxel alone with daily irradiation. Eur. Urol. Oncol. 7, 83\u201390 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1098_CR121","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","volume":"7","author":"A Weickhardt","year":"2024","unstructured":"Weickhardt, A. et al. Pembrolizumab with chemoradiation as treatment for muscle-invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase 2 clinical trial (ANZUP 1502). Eur. Urol. Oncol. 7, 469\u2013477 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1098_CR122","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT02621151 (2025)."},{"key":"1098_CR123","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2020.12.033","volume":"110","author":"G Marcq","year":"2021","unstructured":"Marcq, G. et al. Phase 1 trial of atezolizumab plus trimodal therapy in patients with localized muscle-invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 110, 738\u2013741 (2021).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1098_CR124","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03775265 (2025)."},{"key":"1098_CR125","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.euf.2022.12.012","volume":"9","author":"G Tissot","year":"2023","unstructured":"Tissot, G. & Xylinas, E. Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 Trial. Eur. Urol. Focus. 9, 227\u2013228 (2023).","journal-title":"Eur. Urol. Focus."},{"key":"1098_CR126","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","volume":"39","author":"P Singh","year":"2021","unstructured":"Singh, P. et al. INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: safety update on first 73 patients. J. Clin. Oncol. 39, 428\u2013428 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06470282 (2025)."},{"key":"1098_CR128","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR129","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","volume":"4","author":"CC Peyton","year":"2018","unstructured":"Peyton, C. C. et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer. JAMA Oncol. 4, 1535\u20131542 (2018).","journal-title":"JAMA Oncol."},{"key":"1098_CR130","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00345-022-04012-4","volume":"40","author":"A Arora","year":"2022","unstructured":"Arora, A. et al. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. World J. Urol. 40, 1697\u20131705 (2022).","journal-title":"World J. Urol."},{"key":"1098_CR131","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229\u20131238 (2012).","journal-title":"Eur. Urol."},{"key":"1098_CR132","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1464-410X.2009.08905.x","volume":"105","author":"NJ Hellenthal","year":"2010","unstructured":"Hellenthal, N. J., Ramirez, M. L., Evans, C. P. & DeVere White, R. W. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy. BJU Int. 105, 485\u2013488 (2010).","journal-title":"BJU Int."},{"key":"1098_CR133","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","volume":"192","author":"A Meyer","year":"2014","unstructured":"Meyer, A. et al. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J. Urol. 192, 696\u2013701 (2014).","journal-title":"J. Urol."},{"key":"1098_CR134","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859\u2013866 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR135","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2023.02.008","volume":"6","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin, E. et al. A systematic review of oncological outcomes associated with bladder-sparing strategies in patients achieving complete clinical response to initial systemic treatment for localized muscle-invasive bladder cancer. Eur. Urol. Oncol. 6, 251\u2013262 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1098_CR136","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","volume":"200","author":"P Mazza","year":"2018","unstructured":"Mazza, P. et al. Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study. J. Urol. 200, 1005\u20131013 (2018).","journal-title":"J. Urol."},{"key":"1098_CR137","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","volume":"111","author":"D Robins","year":"2018","unstructured":"Robins, D. et al. Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy. Urology 111, 116\u2013121 (2018).","journal-title":"Urology"},{"key":"1098_CR138","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.euf.2023.01.023","volume":"9","author":"M Egger","year":"2023","unstructured":"Egger, M. & Seiler, R. Which patients to consider for bladder preservation after a complete response to neoadjuvant chemotherapy. Eur. Urol. Focus. 9, 229\u2013231 (2023).","journal-title":"Eur. Urol. Focus."},{"key":"1098_CR139","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","volume":"361","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927\u20131934 (2003).","journal-title":"Lancet"},{"key":"1098_CR140","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.29387","volume":"121","author":"MD Galsky","year":"2015","unstructured":"Galsky, M. D. et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121, 2586\u20132593 (2015).","journal-title":"Cancer"},{"key":"1098_CR141","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister, C. et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 25, 255\u2013264 (2024).","journal-title":"Lancet Oncol."},{"key":"1098_CR142","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.euo.2018.07.009","volume":"2","author":"J Huo","year":"2019","unstructured":"Huo, J. et al. Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer. Eur. Urol. Oncol. 2, 497\u2013504 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"1098_CR143","first-page":"24","volume":"13","author":"JJ Duplisea","year":"2019","unstructured":"Duplisea, J. J. et al. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can. Urol. Assoc. J. 13, 24\u201328 (2019).","journal-title":"Can. Urol. Assoc. J."},{"key":"1098_CR144","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.eururo.2012.01.039","volume":"61","author":"M Burger","year":"2012","unstructured":"Burger, M., Mulders, P. & Witjes, W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur. Urol. 61, 1070\u20131071 (2012).","journal-title":"Eur. Urol."},{"key":"1098_CR145","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","volume":"28","author":"G Basile","year":"2022","unstructured":"Basile, G. et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 Trial. Clin. Cancer Res. 28, 5107\u20135114 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1098_CR146","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"1098_CR147","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102\u20132114 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo, A. B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 392, 45\u201355 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR149","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22, 525\u2013537 (2021).","journal-title":"Lancet Oncol."},{"key":"1098_CR150","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt, S. A. et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J. Clin. Oncol. 40, 1312\u20131322 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR151","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1200\/JCO.23.00363","volume":"41","author":"R Cathomas","year":"2023","unstructured":"Cathomas, R. et al. Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase ii trial SAKK 06\/17. J. Clin. Oncol. 41, 5131\u20135139 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR152","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"1098_CR153","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1470-2045(22)00158-9","volume":"23","author":"SA Hussain","year":"2022","unstructured":"Hussain, S. A. et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol. 23, 650\u2013658 (2022).","journal-title":"Lancet Oncol."},{"key":"1098_CR154","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773\u20131786 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1098_CR155","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03661320 (2025)."},{"key":"1098_CR156","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03924856 (2025)."},{"key":"1098_CR157","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04960709 (2025)."},{"key":"1098_CR158","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03924895 (2025)."},{"key":"1098_CR159","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04700124 (2025)."},{"key":"1098_CR160","unstructured":"Guidelines Detail. NCCN https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417 (2025)."},{"key":"1098_CR161","doi-asserted-by":"publisher","unstructured":"SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS584 (2023).","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS584"},{"key":"1098_CR162","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand, S. et al. Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol. Oncol. 43, 286\u2013296 (2025).","journal-title":"Urol. Oncol."},{"key":"1098_CR163","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/molecules29081896","volume":"29","author":"A Eturi","year":"2024","unstructured":"Eturi, A., Bhasin, A., Zarrabi, K. K. & Tester, W. J. Predictive and prognostic biomarkers and tumor antigens for targeted therapy in urothelial carcinoma. Molecules 29, 1896 (2024).","journal-title":"Molecules"},{"key":"1098_CR164","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1098_CR165","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"1098_CR166","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"1098_CR167","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl, G. et al. Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur. Urol. 81, 523\u2013532 (2022).","journal-title":"Eur. Urol."},{"key":"1098_CR168","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554 (2017).","journal-title":"Eur. Urol."},{"key":"1098_CR169","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"DJ McConkey","year":"2016","unstructured":"McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-na\u00efve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855\u2013862 (2016).","journal-title":"Eur. Urol."},{"key":"1098_CR170","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/JU.0000000000000351","volume":"203","author":"DS Morera","year":"2020","unstructured":"Morera, D. S. et al. Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA. J. Urol. 203, 62\u201372 (2020).","journal-title":"J. Urol."},{"key":"1098_CR171","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00362","volume":"8","author":"U Satyal","year":"2024","unstructured":"Satyal, U. et al. Urine biopsy as dynamic biomarker to enhance clinical staging of bladder cancer in radical cystectomy candidates. JCO Precis. Oncol. 8, e2300362 (2024).","journal-title":"JCO Precis. Oncol."},{"key":"1098_CR172","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR173","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1098_CR174","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen, E. et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin. Cancer Res. 29, 1582\u20131591 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1098_CR175","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"1098_CR176","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05630131 (2025)."},{"key":"1098_CR177","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1016\/j.ijrobp.2024.07.1249","volume":"120","author":"I Epstein","year":"2024","unstructured":"Epstein, I. et al. Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients undergoing trimodality therapy (TMT). Int. J. Radiat. Oncol. Biol. Phys. 120, e564\u2013e565 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1098_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06537154 (2025)."},{"key":"1098_CR179","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140\u20131153 (2014).","journal-title":"Cancer Discov."},{"key":"1098_CR180","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959\u2013967 (2015).","journal-title":"Eur. Urol."},{"key":"1098_CR181","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1200\/JCO-24-01214","volume":"43","author":"DM Geynisman","year":"2025","unstructured":"Geynisman, D. M. et al. Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). J. Clin. Oncol. 43, 1113\u20131122 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR182","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-024-01242-4","volume":"26","author":"VD D\u2019Andrea","year":"2024","unstructured":"D\u2019Andrea, V. D. et al. Impact of DNA repair deficiency in the evolving treatment landscape of bladder cancer. Curr. Urol. Rep. 26, 12 (2024).","journal-title":"Curr. Urol. Rep."},{"key":"1098_CR183","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT04506554 (2025)."},{"key":"1098_CR184","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT03609216 (2025)."},{"key":"1098_CR185","doi-asserted-by":"publisher","first-page":"TPS4615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","volume":"40","author":"G Iyer","year":"2022","unstructured":"Iyer, G. et al. A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701). J. Clin. Oncol. 40, TPS4615\u2013TPS4615 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1098_CR186","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT01261299 (2018)."},{"key":"1098_CR187","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1535-7163.MCT-16-0381","volume":"16","author":"M Zimmermann","year":"2017","unstructured":"Zimmermann, M. et al. Microdose-induced drug-DNA adducts as biomarkers of chemotherapy resistance in humans and mice. Mol. Cancer Ther. 16, 376\u2013387 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"1098_CR188","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/ijc.25814","volume":"129","author":"PT Henderson","year":"2011","unstructured":"Henderson, P. T. et al. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int. J. Cancer 129, 1425\u20131434 (2011).","journal-title":"Int. J. Cancer"},{"key":"1098_CR189","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1158\/1078-0432.CCR-23-0792","volume":"29","author":"SC Kamran","year":"2023","unstructured":"Kamran, S. C. et al. Genomic tumor correlates of clinical outcomes following organ-sparing chemoradiation therapy for bladder cancer. Clin. Cancer Res. 29, 5116\u20135127 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1098_CR190","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT06204614 (2024)."},{"key":"1098_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12543-9","volume":"7","author":"P Gheibi","year":"2017","unstructured":"Gheibi, P. et al. Microchamber cultures of bladder cancer: a platform for characterizing drug responsiveness and resistance in PDX and primary cancer cells. Sci. Rep. 7, 12277 (2017).","journal-title":"Sci. Rep."},{"key":"1098_CR192","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbrc.2019.06.165","volume":"517","author":"AM Mondal","year":"2019","unstructured":"Mondal, A. M. et al. Fidelity of a PDX-CR model for bladder cancer. Biochem. Biophys. Res. Commun. 517, 49\u201356 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1098_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01262-1","volume":"23","author":"R Seiler","year":"2023","unstructured":"Seiler, R. et al. Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial. BMC Urol. 23, 89 (2023).","journal-title":"BMC Urol."},{"key":"1098_CR194","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.euf.2024.08.008","volume":"11","author":"M Radi\u0107","year":"2025","unstructured":"Radi\u0107, M., Egger, M., Kruithof-de Julio, M. & Seiler, R. Patient-derived organoids in bladder cancer: opportunities and challenges. Eur. Urol. Focus 11, 62\u201370, https:\/\/doi.org\/10.1016\/j.euf.2024.08.008 (2025).","journal-title":"Eur. Urol. Focus"},{"key":"1098_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24878","volume":"10","author":"Z Wei","year":"2024","unstructured":"Wei, Z. et al. Development and validation of a CT-based deep learning radiomics nomogram to predict muscle invasion in bladder cancer. Heliyon 10, e24878 (2024).","journal-title":"Heliyon"},{"key":"1098_CR196","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13244-023-01569-5","volume":"15","author":"R Sun","year":"2024","unstructured":"Sun, R. et al. Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study. Insights Imaging 15, 21 (2024).","journal-title":"Insights Imaging"},{"key":"1098_CR197","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1007\/s00330-021-08426-3","volume":"32","author":"G Zhang","year":"2022","unstructured":"Zhang, G. et al. CT-based radiomics to predict muscle invasion in bladder cancer. Eur. Radiol. 32, 3260\u20133268 (2022).","journal-title":"Eur. Radiol."},{"key":"1098_CR198","doi-asserted-by":"publisher","first-page":"176.e9","DOI":"10.1016\/j.urolonc.2024.02.008","volume":"42","author":"L Li","year":"2024","unstructured":"Li, L. et al. Prediction of histopathologic grades of bladder cancer with radiomics based on MRI: comparison with traditional MRI. Urol. Oncol. 42, 176.e9\u2013176.e20 (2024).","journal-title":"Urol. Oncol."},{"key":"1098_CR199","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1016\/j.acra.2024.02.047","volume":"31","author":"Y Cao","year":"2024","unstructured":"Cao, Y., Zhu, H., Li, Z., Liu, C. & Ye, J. CT image-based radiomic analysis for detecting PD-L1 expression status in bladder cancer patients. Acad. Radiol. 31, 3678\u20133687 (2024).","journal-title":"Acad. Radiol."},{"key":"1098_CR200","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S1470-2045(23)00061-X","volume":"24","author":"S Wu","year":"2023","unstructured":"Wu, S. et al. Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study. Lancet Oncol. 24, 360\u2013370 (2023).","journal-title":"Lancet Oncol."},{"key":"1098_CR201","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/cancers16132402","volume":"16","author":"D Sun","year":"2024","unstructured":"Sun, D. et al. Outcome prediction using multi-modal information: integrating large language model-extracted clinical information and image analysis. Cancers 16, 2402 (2024).","journal-title":"Cancers"},{"key":"1098_CR202","first-page":"228","volume":"213","author":"V Sharma","year":"2025","unstructured":"Sharma, V. et al. Artificial intelligence-based assessment of preoperative body composition is associated with early complications after radical cystectomy. J. Urol. 213, 228\u2013237 (2025).","journal-title":"J. Urol."},{"key":"1098_CR203","unstructured":"US National Library of Medicine. ClinicalTrials.gov http:\/\/www.clinicaltrials.gov\/study\/NCT05462561 (2025)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01098-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01098-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:04:29Z","timestamp":1785762269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01098-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":203,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01098-4","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"26 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}